NeoPharm Co Ltd (092730)

Currency in KRW
21,600
+150(+0.70%)
Closed·
092730 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
21,05022,150
52 wk Range
15,59026,000
Key Statistics
Bid/Ask
21,500.00 / 21,550.00
Prev. Close
21,600
Open
21,400
Day's Range
21,050-22,150
52 wk Range
15,590-26,000
Volume
57.09K
Average Volume (3m)
62K
1-Year Change
17.3913%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
092730 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
30,500
Upside
+41.20%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 3 consecutive years

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 30,500
(+41.20% Upside)

Earnings

Latest Release
Nov 13, 2026
EPS / Forecast
-- / --
Revenue / Forecast
39.4B / 41.5B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1,779
Dividend Yield
3.50%
Industry Median 1.02%
Annualized payout
750.00
Paid annually
5-Years Growth
+18.20%
Growth Streak

092730 Income Statement

Compare 092730 to Peers and Sector

Metrics to compare
092730
Peers
Sector
Relationship
P/E Ratio
12.1x8.6x10.7x
PEG Ratio
0.580.110.03
Price/Book
1.7x0.7x1.5x
Price / LTM Sales
2.5x0.8x0.8x
Upside (Analyst Target)
41.2%40.3%21.9%
Fair Value Upside
Unlock31.9%14.1%Unlock

NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea. The company provides Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand name; sensitive, dry, oily, or trouble-prone skin care products under the ZEROID brand; body moisturizers under the Derma-B brand name; sport care products under the MISSION ATHELETCARE brand; and dermArtlogy, a 1:1 consulting cosmetic brand. NeoPharm CO., LTD. was founded in 2000 and is headquartered in Daejeon, South Korea.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
991.42K6.34%21.41B
Other Institutional Investors
7.72M49.36%166.75B
Public Companies & Retail Investors
6.93M44.30%149.68B
Total
15.64M100.00%337.85B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
It'S Hanbul Co., Ltd.42.14%6,590,900142,363,440
Fidelity International Ltd9.63%1,506,14232,532,667

People Also Watch

13,100
017960
-5.82%
23,600
257720
-1.05%
98,400
241710
+2.93%
11,500
083500
-4.01%

FAQ

What Is the NeoPharm (092730) Stock Price Today?

The NeoPharm stock price today is 21,600 KRW.

What Stock Exchange Does NeoPharm Trade On?

NeoPharm is listed and trades on the KOSDAQ.

What Is the Stock Symbol for NeoPharm?

The stock symbol for NeoPharm is "092730."

Does NeoPharm Pay Dividends? What’s The Current Dividend Yield?

The NeoPharm dividend yield is 3.5%%.

What Is the NeoPharm Market Cap?

As of today, NeoPharm market cap is 335.5B KRW.

What Is NeoPharm's Earnings Per Share (TTM)?

The NeoPharm EPS (TTM) is 1,779.

When Is the Next NeoPharm Earnings Date?

NeoPharm will release its next earnings report on Mar 17, 2027.

From a Technical Analysis Perspective, Is 092730 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has NeoPharm Stock Split?

NeoPharm has split 2 times.

How Many Employees Does NeoPharm Have?

NeoPharm has 178 employees.

What is the current trading status of NeoPharm (092730)?

As of Nov 17, 2026, NeoPharm (092730) is trading at a price of 21,600 KRW, with a previous close of 21,600 KRW. The stock has fluctuated within a day range of 21,050 KRW to 22,150 KRW, while its 52-week range spans from 15,590 KRW to 26,000 KRW.

What Is NeoPharm (092730) Price Target According to Analysts?

The average 12-month price target for NeoPharm is 30,500 KRW, with a high estimate of 31000 KRW and a low estimate of 30000 KRW. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +41.20% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.